HCV IRES-dependent expression vector of renilla luciferase
| Clone info. | HCV IRES-dependent expression vector of renilla luciferase. |
|---|---|
| Comment | Expression was confirmed by depositor with Western blotting. |
| Vector backbone | pUC-T7-HCV-HA (Plasmid) |
| Size of vector backbone | 3.4 kb |
| Selectable markers | Amp^r |
| Gene/insert name | Renilla Luciferase cDNA |
| Depositor|Developer | Imataka, Hiroaki | |
Please check terms and conditions set forth by the depositor, which are specified in the RIKEN BRC Catalog and/or Web Catalog.
| Ordering forms | Order form [Credit Card Payment MTA, for use for not-for-profit academic purpose [Word Please visit Information of Request for Distribution.[link] |
|---|---|
| Terms and conditions for distribution | In publishing the research results obtained by use of the BIOLOGICAL RESOURCE, a citation of literature(s) designated by the DEPOSITOR is requested. (J Biol Chem. 289(46): 31960-71, 2014) Additional terms and conditions: The use of the BIOLOGICAL RESOURCE is restricted to the academic researches conducted by non-profit organization. By using this material, the RECIPIENT agrees to be bound by the conditions of the limited use statement of the Promega Corporation. |
[open/close]| 必要書類 | 提供依頼書 提供同意書 (MTA, 非営利学術目的用)[Word 手続きの概要は、「提供申込みについて[link]」をご覧ください。 |
|---|---|
| MTAに書く使用条件 | 利用者は、研究成果の公表にあたって寄託者の指定する文献を引用する (J Biol Chem. 289(46): 31960-71, 2014)。 付加的使用条件: 本件リソースの使用は学術機関での学術研究に限る。本件リソースの使用にあたって、利用者はプロメガ社の限定使用条件に従う必要がある。 |
| Catalog # | Resource name | Availability | Shipping form | Fee |
|---|---|---|---|---|
| RDB13283 | pUC-T7-HCV-HA-Rluc | Under QC test. Please contact us. | DNA solution |
Materials & Methods section:
| The pUC-T7-HCV-HA-Rluc was provided by the RIKEN BRC through the National BioResource Project of the MEXT, Japan (cat. RDB13283). |
Reference section:
| Machida, K., Mikami, S., Masutani, M., Mishima, K., Kobayashi, T., Imataka, H., A translation system reconstituted with human factors proves that processing of encephalomyocarditis virus proteins 2A and 2B occurs in the elongation phase of translation without eukaryotic release factors. J. Biol. Chem. 289 (46), 31960-31971 (2014) PMID 25258322. [PubMed] [Article] [RRC of NBRP] |
Further references such as user reports and related articles (go to bottom)
Please wait for results of QC test to be uploaded. This clone will be sequenced a portion for examination.
Original, user report and related articles
| original | Machida, K., A translation system reconstituted with human factors proves that processing of encephalomyocarditis virus proteins 2A and 2B occurs in the elongation phase of translation without eukaryotic release factors. J. Biol. Chem. 289 (46), 31960-31971 (2014) PMID 25258322. [PubMed] [Article] [RRC of NBRP] |
|---|---|
| reference | Imataka, H., Advantages of human cell-derived cell-free protein synthesis systems (in Japanese text). SEIKAGAKU 81 (4): 303-307 (2009). PMID 19462838. [PubMed] |
Featured content